SCHEMBL4633600

SCHEMBL4633600

CCC(Oc1c(C(=O)Nc2c(F)cccc2F)sc2ccccc12)C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SENP5 Q96HI0 11/20 0.41
SENP2 Q9HC62 11/20 0.41
SENP1 Q9P0U3 11/20 0.41
USP2 O75604 1/20 0.41
CXCR2 P25025 1/20 0.40
F9 P00740 1/20 0.40
F10 P00742 1/20 0.40
PLAU P00749 1/20 0.40
ALDH1A1 P00352 2/20 0.39
PPARG P37231 1/20 0.39
PPARA Q07869 1/20 0.39
LMNA P02545 1/20 0.39
KMT2A Q03164 1/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4633856 0.92 SENP5 (0.42) SENP5SENP2SENP1USP2CXCR2
SCHEMBL4632969 0.90 SENP5 (0.41) SENP5SENP2SENP1USP2CXCR2
SCHEMBL4605028 0.80 KMT2A (0.49) SENP5SENP2SENP1USP2CXCR2
SCHEMBL4604720 0.78 LMNA (0.50) SENP5SENP2SENP1CXCR2ALDH1A1
SCHEMBL4634453 0.78 CXCR2 (0.47) SENP5SENP2SENP1USP2CXCR2
SCHEMBL4603305 0.78 MAOB (0.44) SENP5SENP2SENP1ALDH1A1PPARG
SCHEMBL4606064 0.77 KMT2A (0.44) CXCR2ALDH1A1PPARGPPARALMNA
SCHEMBL4635034 0.77 CXCR2 (0.46) SENP5SENP2SENP1USP2CXCR2
SCHEMBL4633546 0.76 CXCR2 (0.45) SENP5SENP2SENP1USP2CXCR2
SCHEMBL4635082 0.75 KMT2A (0.48) SENP5SENP2SENP1USP2CXCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1685121-B1 ANTIDIABETIC COMPOUNDS COMPRISING BENZOTHIOPHENE DERIVATIVES MERCK PATENT GMBH (DE) 2008-06-11 EP disclosed
US-7375130-B2 Antidiabetic compounds comprising benzofuran and benzothiophene derivatives MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2008-05-20 US disclosed
US-20070078178-A1 Antidiabetic compounds comprising benzofuran and benzothiophene derivatives MERCK PATENT GMBH (DE) 2007-04-05 US disclosed
EP-1685121-A1 ANTIDIABETIC COMPOUNDS COMPRISING BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES MERCK PATENT GmbH (DE) 2006-08-02 EP disclosed
WO-2005054225-A1 ANTIDIABETIC COMPOUNDS COMPRISING BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES MERCK PATENT GMBH (DE) 2005-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078178-A1 Antidiabetic compounds comprising benzofuran and benzothiophene derivatives GPR119, INSR, GLP1R SENP5 2840/4885SENP2 4091/4885SENP1 3148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.